SEOUL - MediThinQ, a South Korea-based surgical visualization technology company, announced today a multi-year exclusive distribution agreement with Synovis Micro Companies Alliance, Inc., a subsidiary of Baxter International Inc. (NYSE:BAX), to commercialize its SHIYA 3D surgical visualization platform globally. Financial terms were not disclosed.Baxter, with a market capitalization of $10.2 billion and revenue of $11.3 billion, is a prominent player in the Healthcare Equipment & Supplies industry, according to InvestingPro analysis. The company currently trades below its Fair Value, placing it among undervalued healthcare stocks. For deeper insights into Baxter’s strategic positioning and growth prospects, investors can access the comprehensive Pro Research Report, available for this and 1,400+ other US equities.
The agreement enables Synovis MCA to distribute SHIYA, a digital surgical platform that combines a high-resolution digital exoscope with up to 20x magnification and a proprietary wearable display called SCOPEYE. The system allows surgeons to operate without traditional eyepieces used in conventional optical microscopes.
SHIYA has been used in more than 100 procedures globally, according to the press release statement. A 2025 review article published in JPRAS Open examined the role of digital exoscope systems in microsurgery, while a separate paper in Plastic and Reconstructive Surgery (PRS 2026) examined portability and ergonomic advantages of 3D exoscopes equipped with heads-up displays.
The platform transitions surgical visualization from optical to digital, allowing procedures to be captured, stored, and shared in real time. The system provides heads-up and wearable configuration designed to support ergonomic surgical workflows and shared visibility across operating teams.
"MediThinQ was founded on the belief that surgeons should not be constrained by the limitations of optical systems," said Seung Joon IM, Founder and CEO of MediThinQ.
Michael Campbell, President of Synovis MCA, stated the company is "honored to work with MediThinQ as their global partner in launching their breakthrough digital vision technology, SHIYA."
The rollout will be phased over time based on regulatory requirements and market readiness in each country. MediThinQ has secured product approvals in the United States, Europe, Japan, China, South Korea, the United Kingdom, Australia, and Taiwan.
Synovis MCA operates in key international markets with relationships across hospitals and reconstructive surgeons built over three decades.
In other recent news, Baxter International Inc. reported stronger-than-expected financial results for the first quarter of 2026. The company achieved earnings per share of $0.36, surpassing the forecasted $0.32, resulting in a 12.5% earnings surprise. Baxter’s revenue also exceeded expectations, reaching $2.7 billion, which is 3.05% higher than anticipated. In addition to its financial performance, Baxter made significant changes to its executive compensation and corporate governance following its 2026 annual meeting. The company approved a new Executive Severance and Change in Control Plan, which affects employees at the vice president level and above. Notably, Chief Executive Officer Andrew Hider’s severance terms were amended to increase the lump-sum cash payment for certain termination cases. Meanwhile, 4D Path announced the first close of a strategic financing round to advance its cancer therapy biomarkers. The company also appointed Katherine Vega Stultz and Robert J. Hombach to its Board of Directors, with Stultz serving as Board Chair.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.
ProPicks AI evaluates BAX alongside thousands of other companies every month using 100+ financial metrics. Using powerful AI to generate exciting stock ideas, it looks beyond popularity to assess fundamentals, momentum, and valuation. The AI has no bias—it simply identifies which stocks offer the best risk-reward based on current data with notable past winners that include Super Micro Computer (+185%) and AppLovin (+157%). Want to know if BAX is currently featured in any ProPicks AI strategies, or if there are better opportunities in the same space?